Chiusura precedente | 26,62 |
Aperto | 27,10 |
Denaro | 0,00 x 0 |
Lettera | 0,00 x 0 |
Min-Max giorno | 26,62 - 26,62 |
Intervallo di 52 settimane | 25,04 - 34,47 |
Volume | |
Media Volume | 6.201 |
Capitalizzazione | 42,281B |
Beta (5 anni mensile) | 0,54 |
Rapporto PE (ttm) | 36,97 |
EPS (ttm) | 0,72 |
Prossima data utili | 09 mag 2024 |
Rendimento e dividendo (futuro) | 1,24 (4,67%) |
Data ex dividendo | 28 mar 2024 |
Stima target 1A | N/D |
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results